Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer

Bergqvist Michael; Holgersson Georg; Bondarenko Igor; Grechanaya Elena; Maximovich Alexey; Andor Gyorgy; Klockare Maria; Thureson Marcus; Jerling Markus; Harmenberg Johan

首页> 外文期刊>Acta oncologica. >Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer

【24h】

Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer

机译：IGF-1R途径调节剂AXL1717的II期随机研究与先前治疗，局部晚期或转移性非小细胞肺癌患者的多西紫杉醇相比

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: The primary objective of this study was to compare the progression-free survival (PFS) at 12 weeks between patients treated with IGF-1R pathway modulator AXL1717 (AXL) and patients treated with docetaxel (DCT).

机译：背景：本研究的主要目的是在用IGF-1R途径调制器AXL1717（AXL）治疗的患者之间的12周内比较无进展的存活（PFS）和用多西紫杉醇（DCT）治疗的患者。

著录项

来源
《Acta oncologica.》 |2017年第6期|共7页
作者
Bergqvist Michael; Holgersson Georg; Bondarenko Igor; Grechanaya Elena; Maximovich Alexey; Andor Gyorgy; Klockare Maria; Thureson Marcus; Jerling Markus; Harmenberg Johan;
展开▼
作者单位

Uppsala Univ Dept Immunol Genet &

Pathol Uppsala Sweden;

Uppsala Univ Dept Immunol Genet &

Pathol Uppsala Sweden;

Dnipropetrovsk Med Acad City Multi Field Clin Hosp 4 Dnepropetrovsk Ukraine;

PSI St Petersburg Russia;

PSI St Petersburg Russia;

PSI Budapest Hungary;

Axelar AB Karolinska Inst Sci Pk Solna Sweden;

Statisticon AB Uppsala Sweden;

Axelar AB Karolinska Inst Sci Pk Solna Sweden;

Axelar AB Karolinska Inst Sci Pk Solna Sweden;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 吉非替尼治疗局部晚期或转移性非小细胞肺癌患者疗效及生存的临床预测因素——两项Ⅱ期临床研究的综合分析 [J] . 赵媛媛, 张阳, 赵洪云, 癌症（英文版） . 2009,第006期
2. Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer [J] . Bergqvist Michael, Holgersson Georg, Bondarenko Igor, Acta oncologica. . 2017,第1a6期

机译：IGF-1R途径调节剂AXL1717的II期随机研究与先前治疗，局部晚期或转移性非小细胞肺癌患者的多西紫杉醇相比
3. Elderly Subset Analysis of Randomized Phase III Study Comparing Pemetrexed Plus Carboplatin with Docetaxel Plus Carboplatin as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer [J] . José Rodrigues Pereira, Rebecca Cheng, Mauro Orlando, Drugs in R&D . 2013,第4期

机译：培美曲塞加卡铂与多西他赛加卡铂作为一线治疗局部晚期或转移性非小细胞肺癌患者的随机III期研究的老年人亚组分析
4. Elderly Subset Analysis of Randomized Phase?III Study Comparing Pemetrexed Plus Carboplatin with Docetaxel Plus Carboplatin as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer [J] . José Rodrigues Pereira, Rebecca Cheng, Mauro Orlando, Drugs in R&D . 2013,第4期

机译：培美曲塞加卡铂与多西他赛加卡铂作为一线治疗局部晚期或转移性非小细胞肺癌患者的随机III期研究的老年人亚组分析
5. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
6. Assessing the effectiveness of palliative chemotherapy for non-small cell lung cancer: A phase IV study of patients treated at Ontario's cancer centres [D] . Harrison, Lyndsay Dawn. 2012

机译：评估姑息化疗对非小细胞肺癌的有效性：在安大略省癌症中心接受治疗的患者的IV期研究
7. The Prognostic Value of Pre-Treatment Leukocytosis in Patients with Previously Treated Stage IIIB/IV Non-Small Cell Lung Cancer Treated with the IGF-1R Pathway Modulator AXL1717 or Docetaxel; a Retrospective Analysis of a Phase II Trial [O] . Georg Holgersson, Michael Bergqvist, Jonas Nilsson, 2017

机译：IGF-1R途径调节剂AXL1717或多西他赛治疗的先前治疗过的IIIB / IV期非小细胞肺癌患者的治疗前白细胞增多症的预后价值；第二阶段试验的回顾性分析
8. Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer [O] . Michael Bergqvist, Georg Holgersson, Igor Bondarenko, 2016

机译：IGF-1R途径调节剂AXL1717的II期随机研究与先前治疗，局部晚期或转移性非小细胞肺癌患者的多西紫杉醇相比

Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer

摘要

著录项

相似文献

相关主题

期刊订阅